Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 85/100

Termination Rate

14.3%

1 terminated out of 7 trials

Success Rate

0.0%

-86.5% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

1 of 0 completed with results

Key Signals

1 with results0

Data Visualizations

Phase Distribution

7Total
Not Applicable (1)
Early P 1 (1)
P 1 (4)
P 2 (1)

Trial Status

Recruiting3
Unknown2
Terminated1
Not Yet Recruiting1

Clinical Trials (7)

Showing 7 of 7 trials
NCT04318678Phase 1Recruiting

CD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)

NCT06648889Phase 2RecruitingPrimary

Isatuximab in Adult Patients With Cytologic or Molecular Relapsed/Refractory CD38 Positive T-cell Acute Lymphoblastic Leukemia

NCT06849401Early Phase 1Not Yet RecruitingPrimary

The Safety and Efficacy of VGO-Cs01p in Patients With CD7-positive Relapsed/Refractory Acute T-lymphoblastic Leukemia

NCT03422679Phase 1Terminated

Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies

NCT06136364Phase 1Recruiting

CD7 CAR-T in Adults With Relapsed or Refractory T-LBL/ALL Clinical Study

NCT05398614Phase 1UnknownPrimary

SENL101 Autologous T Cell Injection in Adults With Relapsed or Refractory CD7+ Hematolymphoid Malignancies

NCT04785833Not ApplicableUnknownPrimary

CD7 CAR-T in the Treatment of CD7 Positive Refractory Relapsed Acute Leukemia

Showing all 7 trials

Research Network

Activity Timeline